Day 1, July 11
8:30-8:45 AM Welcome
Jeffrey D. White, Director, NCI Office of Cancer Complementary and Alternative Medicine

8:45-9:20 Keynote Speaker: Microbial based cancer therapy
Robert M. Hoffman, Univ. of California San Diego and AntiCancer, Inc.

9:20 -11:35 Modes of action of microbial mediated cancer therapy
Chairs: Robert Mufson, DCB/NCI; Phil Daschner, DCB/NCI; Steve Nothwehr, DCTD/NCI; Steve Thorne, Univ. of Pittsburgh

9:20-9:45 Engineered Salmonella for Drug Delivery to Solid Tumor
Neil S. Forbes, Univ. of Massachusetts Amherst

9:45-10:10 In situ vaccination for cancer immunotherapy: treat locally, respond systemically
Steve Fiering, Geisel School of Medicine at Dartmouth

10:10-10:25 Break

10:25-10:50 Oncolytic viruses as novel, multi-mechanistic immunotherapies
Steve Thorne, Univ. of Pittsburgh

10:50-11:15 Viral Vectors as Vaccines Targeting Cancer Antigens
Kim Lyerly, Duke Univ.

11:15-11:35 Panel Discussion

11:35-1:30 LUNCH and POSTER SESSION

1:30-4:45 Bacterial based cancer therapy
Chairs: Elad Sharon, DCTD/NCI; Jacob Kagan, DCP/NCI; Daniel A. Saltzman, Univ. of Minnesota

1:30-1:55 Site-Specific Immunomodulators: Harnessing the Intrinsic Immune Capacity to Prevent and Fight Malignancy
Hal Gunn, Qu Biologics

Robert M. Hoffman, AntiCancer Inc. and Univ. of California San Diego

2:20-2:45 Therapy with Oncolytic Bacterium C. novyi-NT: From Mice to Men
Shibin Zhou, Johns Hopkins Univ.

2:45-3:00 Break

3:00-3:25 Salmonella derived immunotherapy for solid malignancies
Daniel A. Saltzman, Univ. of Minnesota

3:35-4:00 Vectors to Guide Anti-Tumor Immune Responses
James L. Gulley, NIH

4:00-4:25 Insights from Listeria monocytogenes in the Development of Clinical Cancer Immunotherapeutic Approaches
Tom Dubinsky, Aduro Biotech, Inc.

4:25-4:45 Panel Discussion
Day 2, July 12
8:30-8:55 AM Welcome
8:55 -10:45 AM Cancer virotherapy
  Chairs: Jason Yovandich, DCTD/NCI; Richard G Vile, Mayo Clinic
  8:55-9:00 T-VEC, an oncolytic Herpes virus for melanoma treatment.
    Robert H. I. Andtbacka, Univ. of Utah
  9:00-9:25 PVS-RIPO, an Oncolytic immunotherapy based on poliovirus for glioblastoma
    Matthias Gromeier, Duke Univ.
  9:25-9:50 Developing immunomodulatory anti-cancer vectors from tiny viruses
    Peter Tattersall, Yale Univ. School of Medicine
  9:50-10:05 Break
  10:05-10:30 Reovirus Based Therapies for Cancer
    Richard G Vile, Mayo Clinic
  10:30-10:45 Panel Discussion

10:45-11:45 Poster oral presentations
  1. Tumor localized inhibition of the PD1/PDL1 checkpoint enhances the efficacy of oncolytic myxoma virus against both local and metastatic melanoma; Eric Bartee, Medical Univ. of South Carolina
  2. MAP3K7 and CHD1 are novel mediators of resistance to VSV oncolysis in prostate cancer; David a. Ornelles, Wake Forest School of Medicine
  3. Engineered Reoviruses Have Enhanced Oncolytic Properties Against Triple-Negative Breast Cancer; Bernardo A. Mainou, Emory Univ.
  4. Reenergized Adoptive Cell Transfer (ReACT)- A Multi-Pronged Strategy to Treat Solid Tumors; Weiguo Cui, Blood Center of Wisconsin
  5. Cancer therapy in a microbial bottle: Uncorking the remarkable anti-cancer biology of Toxoplasma gondii; David J. Bzik, Geisel School of Medicine at Dartmouth
  6. Cloud-based Microbe Identification and Characterization Pipeline; Hsinyi Tsang, National Cancer Institute

11:45-12:40 LUNCH

12:40-15:20 Bringing microbial based cancer therapy to the patient: Industrial research efforts
  Chairs: Min He, DCTD/NCI; Jonathan Franca-Koh, SBIR/NCI; Grant McFadden, Biodesign Institute
  12:40-1:05 Vectors to Guide Anti-Tumor Immune Responses
    Halle H. Zhang, BioMed Valley Discoveries, Inc.
  1:05-1:30 Cancer bacterial vaccines - live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment
    Robert G. Petit, Advaxis, Inc.
  1:30 1:45 Break
  1:45-2:10 Clinical Considerations on Microbes-based Cancer Therapy - a Regulatory Perspective
    Ke Liu, CBER/FDA
  2:10-2:35 Bacterial minicell-based oncolytic therapy for non-muscle invasive bladder cancer and beyond
    Matthew Giacalone, Vaxiion Therapeutics
  2:35-3:00 Ex vivo virotherapy with oncolytic Myxoma Virus improves cancer-free outcomes after either allo- or auto- hematopoietic stem cell transplantation
    Grant McFadden, Biodesign Institute, Arizona State Univ.,
  3:00-3:20 Panel Discussion